Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
about
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewOptions for empagliflozin in combination therapy in type 2 diabetes mellitusDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesDiabetes DyslipidemiaEmpagliflozinSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysisImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsEffects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesManagement of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Empagliflozin in the treatment of type 2 diabetes: evidence to dateThe effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsEffect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.Short commentary on empagliflozin and its potential clinical impactThe role of empagliflozin in the management of type 2 diabetes by patient profile.Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 DiabetesRenal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusPotential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusEmpagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.
P2860
Q24563917-BF8BB830-04D2-42FC-9E89-BBEFE5D18D06Q26745771-FBCD7775-5238-4095-881D-21A23EF135AAQ26749281-A096A487-1A9C-4060-B396-C75FBB4CB379Q26750905-3A690D2E-2F44-40D9-96E5-B7DE40864426Q26773311-74C80201-CDC8-452C-92EC-5694F580283CQ26864336-7FD387B4-A1BC-4967-BB46-1C01C24DDB12Q27301948-0AB10B2A-2764-4D11-9109-52F2F56E577CQ28072765-7E650F35-4528-401D-A138-9765BE72A5C2Q28076978-A053A3EF-0DE6-439A-8B76-BF719D281664Q28080114-47C084B8-7A5A-4B62-895C-A985450EFC8AQ28553482-58BE9E87-F5DF-471D-A16D-99025BA502C1Q30248634-F7B5B34F-8571-4860-B9DE-C41E742E9CE7Q30249371-CF393578-1A00-4017-B14A-DE818F12817FQ30846870-2AB33A59-1330-43E4-B91D-FDEC867AC641Q31105792-1F7D8B80-D217-4074-AA2E-6BD2BF997100Q31112303-29A6BBCD-E266-44B2-8CDC-9D7BD5B64EB1Q32186373-C4184D65-4C33-43B1-8F4C-17702BE374DBQ33619161-6BB63919-A1F1-4595-A8D0-FBF34288F5B4Q33625568-18B21F7F-22C9-47B6-9F48-ECE834E66F15Q33812170-CFD0285C-E7E7-4539-8994-A36E574CE635Q33837017-589EAD3B-83EC-4E34-9B24-A2B1EC7AD68DQ33890770-51A7D130-F705-4C17-8494-7393AB830D58Q34198692-63FAE7FD-39D3-4CBD-BB56-C7D550309EC2Q34457919-EEDCB7BC-96DD-40AF-8C7B-CBDBCE3D5734Q34502358-B7EDF34F-B978-4570-8F1C-AAA3A0A052F9Q34503796-891178A4-0791-4671-870B-747EF80F04BAQ34973750-3C7E79C2-64EF-414A-A9EF-569102070D64Q35117192-8C554ACE-E459-4F17-A772-C65123DAE29CQ35157497-AC12D697-C705-45F7-AE93-7EBB2E60CF3CQ35528797-DC0A571E-7CC3-4CAF-B0A5-D04C62E936F6Q35592873-0F1836D2-2ECD-4AA0-9CE8-6EEA510490B3Q36257565-58F19213-05FC-44D2-A346-A86DE080312BQ36333760-E0ED7E43-3668-4791-968F-E576EEB3994DQ36345951-66D4F69C-7E66-431B-855E-DF29CAB5BB28Q36354599-834A6FB7-B4DE-4919-AFF6-B0B0B2358916Q36402095-92F461B6-E2DB-4F7C-B85A-4C1C416331D2Q36555418-4CBAC535-7AB9-4C80-AFA5-A8189671098EQ36592820-29914E05-DCCE-48C8-8B55-03AC7D556D5FQ36622125-77086986-877F-4010-B4EA-C89F01E7A3F1Q36960633-86789FBD-34AF-4FA7-96DE-1F4F2CD40C0D
P2860
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Empagliflozin monotherapy with ...... ebo-controlled, phase 3 trial.
@en
Empagliflozin monotherapy with ...... ebo-controlled, phase 3 trial.
@nl
type
label
Empagliflozin monotherapy with ...... ebo-controlled, phase 3 trial.
@en
Empagliflozin monotherapy with ...... ebo-controlled, phase 3 trial.
@nl
prefLabel
Empagliflozin monotherapy with ...... ebo-controlled, phase 3 trial.
@en
Empagliflozin monotherapy with ...... ebo-controlled, phase 3 trial.
@nl
P2093
P921
P1476
Empagliflozin monotherapy with ...... cebo-controlled, phase 3 trial
@en
P2093
EMPA-REG MONO trial investigators
Gabriel Kim
Hans J Woerle
Jens Eilbracht
Jianping Weng
Michael Roden
Uli C Broedl
P304
P356
10.1016/S2213-8587(13)70084-6
P577
2013-09-09T00:00:00Z